Journal of Nuclear Medicine: 56 (3)

March 1, 2015; Volume 56,Issue 3

Cover image

In a first clinical trial of prostate cancer, ¹⁸F-BAY 864367 showed favorable dosimetry, safety, and the potential of gastrin-releasing-peptide receptor imaging. See page 372.

In this issue

Issue highlights

MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
Prediction of ¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to